Rabeprazole Sodium + Itopride HydrochlorideThird Party Manufacturing in India

Rabeprazole Sodium + Itopride Hydrochloride is a dual-action fixed-dose combination that targets gastrointestinal acid-related disorders through complementary pharmacological pathways. Rabeprazole sodium, a substituted benzimidazole proton pump inhibitor, accumulates in the acidic secretory canaliculi of gastric parietal cells where it undergoes protonation and conversion to an active sulfenamide intermediate. This reactive species forms covalent disulfide bonds with cysteine residues on the H⁺/K⁺-ATPase enzyme, producing irreversible inhibition of the proton pump and effectively blocking the final common pathway of gastric acid secretion. Itopride hydrochloride offers a unique dual prokinetic mechanism that differentiates it from other motility agents. It acts as a dopamine D₂ receptor antagonist, blocking the inhibitory effects of dopamine on gastric motility, and simultaneously inhibits acetylcholinesterase, increasing the synaptic concentration of acetylcholine at muscarinic receptors in the gastrointestinal tract. This combined action enhances lower esophageal sphincter pressure, accelerates gastric emptying, improves antroduodenal coordination, and stimulates colonic motility. The sustained-release formulation of itopride at 150mg ensures prolonged prokinetic activity throughout the day, while rabeprazole provides consistent acid suppression, making this combination particularly effective for patients with both acid hypersecretion and significant motility impairment.

Therapeutic Uses

Rabeprazole Sodium + Itopride Hydrochloride is prescribed for the treatment of:

• Gastroesophageal Reflux Disease (GERD): For patients with GERD who experience inadequate symptom control with PPI alone, particularly those with prominent regurgitation, belching, and delayed gastric emptying.
• Functional Dyspepsia: For the management of meal-related symptoms including epigastric pain, postprandial fullness, early satiety, nausea, and bloating in patients with functional dyspepsia.
• Chronic Gastritis: For symptomatic relief in chronic superficial and atrophic gastritis with associated dysmotility symptoms.
• Diabetic Gastroparesis: For improving gastric emptying and reducing symptoms of nausea, vomiting, and abdominal discomfort in patients with diabetic gastroparesis.

Why Manufacturers Choose Rabeprazole Sodium + Itopride Hydrochloride

Itopride has emerged as a preferred prokinetic agent in the Indian market due to its dual mechanism of action and favorable safety profile compared to older prokinetics like metoclopramide. The sustained-release tablet formulation of 20mg rabeprazole plus 150mg itopride SR offers once-daily dosing convenience, which is a significant competitive advantage in the crowded gastrointestinal segment. The combination targets a large patient population with functional dyspepsia and GERD, conditions that affect a substantial proportion of the Indian population due to dietary habits and lifestyle factors. For third party manufacturers, this combination offers an opportunity to differentiate their product portfolio with a modern prokinetic agent that has growing clinician acceptance. WHO-GMP certified facilities with expertise in sustained-release tablet technology can efficiently produce this combination for PCD franchise distribution and institutional supply to hospitals and nursing homes.

This makes Rabeprazole Sodium + Itopride Hydrochloride a strong candidate for third party manufacturing in India, with increasing demand from PCD franchise operators and hospital supply chains.